NBI-6024
- Generic Name
- NBI-6024
- Drug Type
- Biotech
- Unique Ingredient Identifier
- OMF3CT7D4L
- Background
NBI-6024 is an altered peptide ligand that is designed to cause an immune response which result in preservation of beta-cell function and endogenous insulin production.
- Indication
Investigated for use/treatment in diabetes mellitus type 1 and pediatric indications.
A Study to Evaluate NBI-6024 in Adult and Adolescent Patients With New Onset of Type 1 Diabetes Mellitus
- First Posted Date
- 2009-04-01
- Last Posted Date
- 2009-04-01
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 188
- Registration Number
- NCT00873561
- Locations
- 🇨🇿
University Hospital and School of Medicine, Olomouc, Czech Republic
🇨🇿Faculty Hospital Motol, Prague, Czech Republic
🇫🇮Helsinki University Hospital, Helsinki, Finland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath